A PHASE II RANDOMIZED CONTROLLED TRIAL OF NIVOLUMAB IN COMBINATION WITH BMS-986253 OR CABIRALIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PATIENTS

Brief description of study

The purpose of this research study is to determine whether treatment with Cabiralizumab or HuMax-IL8 in combination with Nivolumab has additional benefit to Nivolumab treatment alone for treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer.


Clinical Study Identifier: s18-01028
ClinicalTrials.gov Identifier: NCT04050462


If you are registered as a volunteer, please login to the dashboard to send referrals.